Japan's Cell and Gene Therapy Market 2025-2033

The market size for cell and gene therapy in Japan was valued at 727 million USD in 2024. Going forward, the IMARC Group estimates a CAGR of 12% from 2025 to 2033, projecting the market to reach 2.016 billion USD by 2033.
The Japanese cell and gene therapy market is rapidly growing, driven by strong government support, advanced research and development, and the expansion of approvals for regenerative medicine products. Innovations in CAR-T, iPSC, and gene editing therapies are being accelerated through collaborations with leading companies such as Takeda Pharmaceutical and Daiichi Sankyo, as well as global biotechnology firms.
The report analyzes key trends in each market segment and provides country-level forecasts for the period from 2025 to 2033. It is segmented based on type of therapy, indications, delivery modes, and end-users.
This report offers a detailed analysis of the competitive landscape, highlighting market structure, positioning of key players, strategies, competitive dashboards, and corporate assessment quadrants.
Email: sales@imarcgroup.com

Inquiry about this news
Contact Us OnlineMore Details & Registration
Details & Registration